TIPS for management of refractory ascites: response and survival are both unpredictable
- PMID: 12757168
- DOI: 10.1023/a:1022544917898
TIPS for management of refractory ascites: response and survival are both unpredictable
Abstract
Refractory ascites is a serious complication of advanced cirrhosis with a 1-year transplant-free survival of 20-50%. The aim of our study was to investigate the short- and long-term effects of transjugular intrahepatic portosystemic shunt (TIPS) in the management of refractory ascites. In all 65 patients (39 M, 26 F; Child B 55%, Child C 45%, mean MELD score 14.8 +/- 6.6) with liver disease (alcoholic 40%, cryptogenic 20%, HCV 14%, others 26%) and refractory ascites were included in this study. Forty-eight (74%) patients had no signs of hepatic encephalopathy (HE), 16 (24%) had mild and 1 (2%) had moderate HE before TIPS; 28 (43%) had mild (> 1.2 and < 2.4 mg/dl) and 6 patients (9%) had moderate (> 2.4 mg/dl) renal dysfunction. Mean follow-up was 55.5 +/- 70.2 weeks. Treatment success, defined as complete response, partial response, and no response, and survival was determined at 3 weeks, and 3, 6, 12, 24, and 36 months after TIPS. TIPS was successful in all patients. Mean portal venous pressure gradient improved significantly after TIPS (24 +/- 8 to 10 +/- 4). During follow-up, 40 (58%) patients died and 17 (27%) patients had liver transplantation (OLT); 20 (31%) patients had 38 shunt revisions due to lack of initial response or recurrence of ascites. The response was assessed in patients who were alive, without OLT, at each time point. Complete response was seen in 10%, 23%, 17%, 11%, 22% and 33%; partial response was seen in 46%, 46%, 40%, 44%, 28%, and 8%; and no response was seen in 44%, 31%, 43%, 41 %, 39%, and 50% at 3 weeks, and 3, 6, 12, 24, and 36 months respectively. There were no pre-TIPS variables that could predict the response at 3 weeks, 3 months, or 6 months. Mild HE was seen in 8 (12%) patients and severe HE was seen in 16 (25%) immediately after TIPS. The mortality at 3 weeks, and 3, 6, 12, 24, and 36 months was 26%, 38%, 46%, 51%, 57%, and 58%, respectively. Three-week (P = 0.01) and 3-month (P = 0.04) mortality was higher in Child C patients compared to Child B. However, there were no independent predictors of survival on multivariate analysis at 3 or 6 months. Child-Pugh score 3 weeks after TIPS was a strong predictor of mortality. In conclusion, in patients with refractory ascites, TIPS was associated with a high mortality and morbidity. The response and the mortality were both unpredictable on the basis of pretransplant variables.
Similar articles
-
Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.Eur J Gastroenterol Hepatol. 2019 May;31(5):626-632. doi: 10.1097/MEG.0000000000001342. Eur J Gastroenterol Hepatol. 2019. PMID: 30550458
-
Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites.Gastroenterology. 2017 Jan;152(1):157-163. doi: 10.1053/j.gastro.2016.09.016. Epub 2016 Sep 20. Gastroenterology. 2017. PMID: 27663604 Clinical Trial.
-
Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome.J Vasc Interv Radiol. 2010 Feb;21(2):218-23. doi: 10.1016/j.jvir.2009.10.025. J Vasc Interv Radiol. 2010. PMID: 20123207
-
TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis.World J Gastroenterol. 2014 Mar 14;20(10):2704-14. doi: 10.3748/wjg.v20.i10.2704. World J Gastroenterol. 2014. PMID: 24627607 Free PMC article. Review.
-
Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality.Am J Gastroenterol. 2003 Nov;98(11):2521-7. doi: 10.1111/j.1572-0241.2003.08664.x. Am J Gastroenterol. 2003. PMID: 14638358 Review.
Cited by
-
TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial.Ann Surg. 2004 Jun;239(6):883-9; discussion 889-91. doi: 10.1097/01.sla.0000128309.36393.71. Ann Surg. 2004. PMID: 15166968 Free PMC article. Clinical Trial.
-
Outcomes After Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients 70 Years and Older.J Clin Med. 2020 Jan 31;9(2):381. doi: 10.3390/jcm9020381. J Clin Med. 2020. PMID: 32023959 Free PMC article.
-
In vivo validation of 4D flow MRI for assessing the hemodynamics of portal hypertension.J Magn Reson Imaging. 2013 May;37(5):1100-8. doi: 10.1002/jmri.23906. Epub 2012 Nov 12. J Magn Reson Imaging. 2013. PMID: 23148034 Free PMC article.
-
Synergism between hepatocellular injury and shunting in portosystemic encephalopathy (PSE): case report of acute brittle TIPS-induced PSE.Dig Dis Sci. 2007 Nov;52(11):3270-4. doi: 10.1007/s10620-006-9371-2. Epub 2007 Jul 20. Dig Dis Sci. 2007. PMID: 17638078 No abstract available.
-
Fifteen years' experience with transjugular intrahepatic portosystemic shunt (TIPS) using bare stents: retrospective review of clinical and technical aspects.Radiol Med. 2009 Feb;114(1):83-94. doi: 10.1007/s11547-008-0349-3. Epub 2008 Dec 11. Radiol Med. 2009. PMID: 19082786 English, Italian.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical